UNCY insider transaction filings
Unicycive Therapeutics, Inc. — 23 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-28. Screen UNCY transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-28 | 4/A | Laumas Sandeep — Director | Grant/award (A): 47,941 (derivative) @ $0 | EDGAR |
| 2026-07-28 | 4/A | Kenkare-Mitra Sara — Director | Grant/award (A): 47,941 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4/A | Gupta Shalabh K. — CEO, Director | Grant/award (A): 762,200 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4/A | Kenkare-Mitra Sara — Director | Grant/award (A): 84,200 (derivative) @ $0 · Grant/award (A): 42,100 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4/A | Gupta Pramod — EVP, Pharmaceuticals and BD | Grant/award (A): 169,500 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4/A | Jermasek Douglas — EVP, Corporate Strategy | Grant/award (A): 169,500 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4/A | Laumas Sandeep — Director | Grant/award (A): 84,200 (derivative) @ $0 · Grant/award (A): 42,100 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4/A | Townsend John — CFO | Grant/award (A): 169,500 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Gupta Shalabh K. — CEO, Director | Grant/award (A): 762,200 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Kenkare-Mitra Sara — Director | Grant/award (A): 84,200 (derivative) @ $0 · Grant/award (A): 42,100 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Jermasek Douglas — EVP, Corporate Strategy | Grant/award (A): 169,500 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Gupta Pramod — EVP, Pharmaceuticals and BD | Grant/award (A): 169,500 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Townsend John — CFO | Grant/award (A): 169,500 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Laumas Sandeep — Director | Grant/award (A): 84,200 (derivative) @ $0 · Grant/award (A): 42,100 (derivative) @ $0 | EDGAR |
| 2025-08-26 | 4 | Aggarwal Gaurav — Director | Conversion (C): 652,900 · Disposition to issuer (D): 3,199.21 (derivative) @ $1,000 | EDGAR |
| 2025-07-30 | 4 | Kenkare-Mitra Sara — Director | Grant/award (A): 21,200 (derivative) @ $0 | EDGAR |
| 2025-07-30 | 4 | Gupta Shalabh K. — CEO, Director | Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2025-07-30 | 4 | Gupta Pramod — EVP, Pharmaceuticals and BD | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-07-30 | 4 | Jermasek Douglas — EVP of Corporate Strategy | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-07-30 | 4 | Laumas Sandeep — Director | Grant/award (A): 21,200 (derivative) @ $0 | EDGAR |
| 2025-07-30 | 4 | Aggarwal Gaurav — Director | Grant/award (A): 21,200 (derivative) @ $0 | EDGAR |
| 2025-07-30 | 4 | Townsend John — Chief Financial Officer | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Aggarwal Gaurav — Director | Conversion (C): 1,400,000 · Disposition to issuer (D): 686 (derivative) @ $1,000 | EDGAR |
Recent 8-K events — Unicycive Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-28 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=UNCY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →